Quidel logo — Follow us now at linkedin.com/company/quidelortho/

Quidel

Follow us now at linkedin.com/company/quidelortho/

Founded 1979 United States San Diego, United States 502 employees IPO Total: $630.00K Biotechnology, Health Care +2

General Information

Company Name Quidel
Founded Year 1979
Location United States San Diego, United States
Employees 502
Industries Biotechnology, Health Care, Manufacturing +1
Funding Stage IPO
Business Model B2B, D2C, B2B2C
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Quidel. To contact Quidel, visit quidel.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Quidel compare?

A PDF of Quidel and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Quidel soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Quidel

Quidel is a longstanding entity in the biotechnology and healthcare sectors, founded in 1979 and headquartered in the United States. With a focus on developing and manufacturing intelligent diagnostic solutions, QuidelOrtho is dedicated to transforming data into actionable insights, enhancing early trend detection, and providing decisive and accurate analysis for global health improvement.

This company operates at the intersection of Biotechnology, Health Care, Manufacturing, and Pharmaceutical industries, positioning itself as a critical player in advancing diagnostics for a healthier future. Their innovative solutions cater to diverse markets and contribute significantly to efficient healthcare delivery systems.

The most recent financial boost was a $630.00K grant investment received on 01 May 2020, highlighting a favorable reception of its strategic initiatives. This financial backing underscores its reputation and potential for sustainable growth in the rapidly evolving healthcare landscape.

Business keywords: Point-of-Care Diagnostics, Infectious Disease Testing, Reproductive Health Diagnostics, Women's Health Diagnostics, Lateral Flow Assays, Fluorescent Immunoassays, Molecular Diagnostics, Isothermal Amplification Technology, Healthcare Data Solutions, Veterinary Diagnostics, Clinical Laboratory Tests, Immunoassay Tests, Circulating Immune Complex Measurement, Medical Device Manufacturing, Healthcare Distribution Partnerships

Services & Products

COVID-19 Testing
Laboratory Management
Automated Immunohematology Systems
Rapid Diagnostic Testing

Target Customers

Laboratory Professionals Healthcare Providers Home Users Transfusion Labs

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $630.00K -
01 May 2020
IPO Undisclosed -
01 Aug 1981

Quidel Alternatives & Competitors

View All Alternatives
Quidel vs

Revolutionizing Molecular Diagnostics with world-class Innovative IVD Solutions.

103 employees
Biotechnology, Health Care
Quidel vs
Aidian
Aidian Finland

Aidian develops, manufactures and markets diagnostic tests and test solutions.

Venture round
205 employees
Biotechnology, Health Care
Quidel vs

The Ideal Choice for Cost-Effective High Throughput Syndromic Panels

Venture round
60 employees
Biotechnology, Health Care

FAQ About Quidel

Follow us now at linkedin.com/company/quidelortho/
Quidel was founded in 1979.
Quidel is headquartered in San Diego, United States.
Quidel operates in Biotechnology, Health Care, Manufacturing and Pharmaceutical. Its work centres on Point-of-Care Diagnostics, Infectious Disease Testing, Reproductive Health Diagnostics and Women's Health Diagnostics. Its customers include Laboratory Professionals, Healthcare Providers and Home Users.
Quidel has a B2B, D2C and B2B2C business model. Its revenue comes from Product Sales, Service Fee and Licensing.
Quidel has approximately 502 employees.
Quidel has completed 2 funding rounds, raising a total of $630.00K. The latest funding stage is IPO.
Quidel offers: COVID-19 Testing, Laboratory Management, Automated Immunohematology Systems, Rapid Diagnostic Testing.
Top alternatives and competitors to Quidel include G2M | Next Generation IVD solutions for Genomics, Aidian, Applied BioCode, Inc., Nanjing Poclight Biotechnology Co., Ltd, All Eights. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Quidel and G2M | Next Generation IVD solutions for Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Quidel, https://bouncewatch.com/company/quidel, updated 13 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes